Literature DB >> 17659846

Total testosterone, androgen receptor polymorphism, and depressive symptoms in young black and white men: the CARDIA Male Hormone Study.

Laura A Colangelo1, Lisa Sharp, Peter Kopp, Denise Scholtens, Brian C-H Chiu, Kiang Liu, Susan M Gapstur.   

Abstract

Androgen receptor (AR) CAG repeat length (RL) might modify the relationship between endogenous testosterone (T) and depressive symptoms in men on average over age 50 years. We hypothesized that CAG RL modifies the association between T and depressive symptoms in 525 black and 721 white men under age 40 years participating in the CARDIA Male Hormone Study. We assessed cross-sectional associations of quartiles of total and bioavailable T and tertiles of CAG RL with depressive symptoms, defined as Center for Epidemiologic Studies Depression Scale (CES-D) score > or=16, in 1995-1996. The interaction of CAG RL and total T on depressive symptoms was statistically significant for blacks, whites, and both groups combined. In the combined analysis, the odds ratios (OR) (95% confidence intervals (CI)) across the quartiles of total T were 1.00, 0.17 (95% CI=0.07-0.43), 0.31 (95% CI=0.14-0.70), and 0.49 (95% CI=0.22-1.09) for the shortest RL group. The interaction of CAG RL and bioavailable T on depressive symptoms was statistically significant for black men only, and nonsignificant in a combined analysis. For black men in the shortest RL group, the ORs for the quartiles of bioavailable T were 1.00, 0.41 (95% CI=0.16-1.05), 0.10 (95% CI=0.03-0.38), and 0.35 (95% CI=0.14-0.90). In other CAG groups, there were no relationships of total or bioavailable T with depressive symptoms. CAG RL might modify the association between endogenous total and bioavailable T and depressive symptoms in younger black men. Clinical trials assessing the effects of T replacement therapy on depressive symptoms in hypogonadal men should consider including CAG RL in their design and/or analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659846      PMCID: PMC2139978          DOI: 10.1016/j.psyneuen.2007.06.014

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  39 in total

1.  Bioavailable testosterone as a correlate of cognition, psychological status, quality of life, and sexual function in aging males: implications for testosterone replacement therapy.

Authors:  P J Perry; B C Lund; S Arndt; T Holman; K A Bever-Stille; J Paulsen; L M Demers
Journal:  Ann Clin Psychiatry       Date:  2001-06       Impact factor: 1.567

2.  Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men.

Authors:  S N Seidman; A B Araujo; S P Roose; J B McKinlay
Journal:  Biol Psychiatry       Date:  2001-09-01       Impact factor: 13.382

3.  Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men.

Authors:  S Grinspoon; C Corcoran; T Stanley; A Baaj; N Basgoz; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

4.  Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men.

Authors:  K Krithivas; S M Yurgalevitch; B A Mohr; C J Wilcox; S J Batter; M Brown; C Longcope; J B McKinlay; P W Kantoff
Journal:  J Endocrinol       Date:  1999-07       Impact factor: 4.286

5.  Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  S N Seidman; E Spatz; C Rizzo; S P Roose
Journal:  J Clin Psychiatry       Date:  2001-06       Impact factor: 4.384

Review 6.  Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory.

Authors:  G Fink; B Sumner; R Rosie; H Wilson; J McQueen
Journal:  Behav Brain Res       Date:  1999-11-01       Impact factor: 3.332

7.  A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms.

Authors:  J G Rabkin; G J Wagner; R Rabkin
Journal:  Arch Gen Psychiatry       Date:  2000-02

8.  Testosterone and men's depression: the role of social behavior.

Authors:  A Booth; D R Johnson; D A Granger
Journal:  J Health Soc Behav       Date:  1999-06

9.  Low testosterone levels in elderly men with dysthymic disorder.

Authors:  Stuart N Seidman; Andre B Araujo; Steven P Roose; D P Devanand; Shan Xie; Thomas B Cooper; John B McKinlay
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

10.  Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study.

Authors:  E Barrett-Connor; D G Von Mühlen; D Kritz-Silverstein
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

View more
  7 in total

Review 1.  Polymorphisms in sex steroid receptors: From gene sequence to behavior.

Authors:  Donna L Maney
Journal:  Front Neuroendocrinol       Date:  2017-07-10       Impact factor: 8.606

Review 2.  The dominance behavioral system and psychopathology: evidence from self-report, observational, and biological studies.

Authors:  Sheri L Johnson; Liane J Leedom; Luma Muhtadie
Journal:  Psychol Bull       Date:  2012-04-16       Impact factor: 17.737

Review 3.  The genetics of sex differences in brain and behavior.

Authors:  Tuck C Ngun; Negar Ghahramani; Francisco J Sánchez; Sven Bocklandt; Eric Vilain
Journal:  Front Neuroendocrinol       Date:  2010-10-15       Impact factor: 8.606

Review 4.  Sex steroid-related candidate genes in psychiatric disorders.

Authors:  Lars Westberg; Elias Eriksson
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

5.  Interactions between genotype and depressive symptoms on obesity.

Authors:  Bernard F Fuemmeler; Tanya Agurs-Collins; F Joseph McClernon; Scott H Kollins; Melanie E Garrett; Allison E Ashley-Koch
Journal:  Behav Genet       Date:  2009-04-01       Impact factor: 2.805

6.  Hair androgen concentrations and depressive disorders in adolescents from the general population.

Authors:  Hanna Kische; Catharina Voss; Robin Haring; Theresa Magdalena Ollmann; Lars Pieper; Clemens Kirschbaum; Katja Beesdo-Baum
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-02-02       Impact factor: 4.785

7.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.